Alzheimer's Disease Lysosomal and Proteostasis Modulation Companies

Overview

This category covers biotechnology and pharmaceutical companies developing therapeutics that target lysosomal dysfunction, autophagy impairment, and proteostasis network disruption in Alzheimer's disease. These approaches address the fundamental cellular protein clearance and organelle maintenance deficits that are central to AD pathogenesis.

Overview

This category covers biotechnology and pharmaceutical companies developing therapeutics that target lysosomal dysfunction, autophagy impairment, and proteostasis network disruption in Alzheimer's disease. These approaches address the fundamental cellular protein clearance and organelle maintenance deficits that are central to AD pathogenesis.

Lysosomal dysfunction is one of the earliest features of Alzheimer's disease, preceding clinical symptoms by decades. Impairments in lysosomal acidification, reduced enzyme activity, and impaired autophagosome-lysosome fusion lead to accumulation of damaged proteins and organelles. The proteostasis network — comprising molecular chaperones, the ubiquitin-proteasome system, and autophagy-lysosomal pathways — becomes progressively overwhelmed in AD, contributing to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) aggregation.

Key Companies

Lysosomal Enzyme Enhancement

Gain Therapeutics

• Focus: Glucocerebrosidase (GCase) modulators and therapeutic chaperones
• Lead Candidate: GT-02287
• Indication: Alzheimer's disease (preclinical), Parkinson's disease (Phase 1b)
• Mechanism: Allosteric small molecule chaperones that stabilize misfolded GCase, enhancing lysosomal enzyme activity and reducing glycosphingolipid accumulation
• Platform: SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules)
• Page: [Gain Therapeutics](/companies/gain-therapeutics)

Lysoway Therapeutics

• Focus: Lysosomal enzyme modulation and integrity
• Lead Candidates: LT-001, LT-002, LT-003
• Indication: Alzheimer's disease, Parkinson's disease
• Mechanism: Small molecule GCase modulators, autophagy enhancers, and lysosomal membrane protectors
• Stage: Discovery/Preclinical
• Page: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

Autophagy Induction

Retro Biosciences

• Focus: Autophagy enhancement and cellular clearance
• Lead Candidate: RB-001
• Indication: Alzheimer's disease
• Stage: Phase 1
• Mechanism: Macroautophagy enhancement to clear protein aggregates and damaged organelles
• Notes: Also developing senolytic approaches
• Page: [Retro Biosciences](/companies/retro-biosciences)

Lyterian Therapeutics

• Focus: Autophagy modulation
• Lead Candidate: LTN-001
• Indication: Alzheimer's disease
• Stage: Preclinical
• Mechanism: mTOR-independent autophagy enhancers targeting TFEB pathway

Proteasome Modulation

Proteostasis Therapeutics

• Focus: Ubiquitin-proteasome system modulation
• Lead Candidate: PT-101
• Indication: Alzheimer's disease, Parkinson's disease
• Stage: Preclinical
• Mechanism: Selective 20S proteasome activators to enhance protein clearance
• Page: [Proteostasis Therapeutics](/companies/proteostasis-therapeutics)

Molecular Chaperone Modulation

Iduna Therapeutics

• Focus: Heat shock protein (HSP) modulators
• Lead Candidate: IDN-001
• Indication: Alzheimer's disease, Parkinson's disease
• Stage: Preclinical
• Mechanism: HSP70 modulators to enhance protein refolding and clearance; HSP90 selective inhibition
• Page: [Iduna Therapeutics](/companies/iduna-therapeutics)

Lysosomal-TREM2 Biology

Alector Inc.

• Focus: TREM2 agonists and lysosomal function
• Lead Candidates: AL002, AL044
• Indication: Alzheimer's disease
• Stage: Phase 1/2
• Mechanism: TREM2 agonism to enhance microglial lysosomal function, phagocytosis, and clearance of amyloid plaques
• Page: [Alector](/companies/alector)

Computational/AI Approaches

Cyclica

• Focus: AI-driven protein homeostasis drug discovery
• Lead Candidates: CC-201, CC-202, CC-203
• Indication: Alzheimer's disease
• Stage: Phase 1/Preclinical
• Mechanism: Protein homeostasis modulators, tau aggregation inhibitors, molecular chaperone enhancers
• Platform: MatchMaker™ AI technology
• Page: [Cyclica](/companies/cyclica)

Additional Companies

| Company | Focus | Mechanism | Stage |
|---------|-------|-----------|-------|
| Heqix Therapeutics | Autophagy induction | mTOR modulators | Discovery |
| Neuromito Therapeutics | Mitochondrial-lysosomal crosstalk | Mitochondrial antioxidants + autophagy | Preclinical |
| Cyteir Therapeutics | Mitochondrial dynamics | Mitochondrial quality control | Discovery |
| Prothelia | Protein homeostasis | Synaptic protection + proteostasis | Preclinical |

Therapeutic Mechanisms

Lysosomal Targeting Approaches

Autophagy Enhancement

Proteostasis Network

Pipeline Summary

| Company | Drug | Mechanism | Phase | Target |
|---------|------|-----------|-------|--------|
| Gain Therapeutics | GT-02287 | GCase chaperone | Phase 1b (PD)/Preclinical (AD) | Lysosomal enzyme |
| Retro Biosciences | RB-001 | Autophagy enhancer | Phase 1 | Autophagy |
| Alector | AL002 | TREM2 agonist | Phase 1/2 | Lysosomal function |
| Cyclica | CC-201 | Proteostasis modulator | Phase 1 | Protein clearance |
| Proteostasis Therapeutics | PT-101 | Proteasome activator | Preclinical | Proteasome |
| Iduna Therapeutics | IDN-001 | HSP70 modulator | Preclinical | Chaperones |
| Lysoway Therapeutics | LT-001 | GCase modulator | Preclinical | Lysosomal enzyme |

Research Context

Lysosomal Dysfunction in Alzheimer's Disease

Lysosomal dysfunction is a hallmark of Alzheimer's disease:

• Acidification Defects: Reduced V-ATPase activity impairs lysosomal acidification
• Enzyme Deficiency: Reduced cathepsin activity degrades protein clearance capacity
• Autophagosome Accumulation: Impaired fusion between autophagosomes and lysosomes
• Lipid Accumulation: Glucosylceramide and other lipids accumulate, disrupting function
• GBA1 Connection: GBA1 mutations (linked to PD) may also increase AD risk

Autophagy Impairment in AD

The autophagy-lysosomal system shows specific defects in AD:

• Early Impairment: Autophagy induction declines before amyloid pathology
• TFEB Dysregulation: Master regulator of lysosomal biogenesis is suppressed
• Impaired Flux: Autophagosomes accumulate but fail to fuse with lysosomes
• Amyloid Clearance: Reduced capacity to clear amyloid-beta aggregates
• Tau Clearance: Impaired autophagy contributes to tau tangle formation

Proteostasis Network Collapse

The proteostasis network becomes progressively overwhelmed:

• Chaperone Capacity: HSP70/90 systems become saturated with misfolded proteins
• Proteasome Inhibition: 20S proteasome activity reduced in AD brains
• Ubiquitin Accumulation: Excess ubiquitin conjugates indicate overwhelmed degradation
• Aggregation Seeding: Misfolded proteins seed toxic aggregate formation

Cross-Links

• [Lysosomal Dysfunction in Alzheimer's Disease](/mechanisms/lysosomal-dysfunction)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy)
• [Protein Homeostasis Network](/mechanisms/protein-homeostasis)
• [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Pathology](/mechanisms/tau-pathology-pathway)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [AD Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies)
• [AD Senolytic Therapy Companies](/companies/ad-senolytic-therapy-companies)

References